Miracle Wangsuwana, DO
Neurology · North Las Vegas, NVNPI 1750377693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,643 and has fallen 82.2% since, to $471 in 2025.
Across 175 payments — averaging $52.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- Novartis$1K
- EMD Serono, Inc.$922
- AbbVie$704
- UCB, Inc.$626
- Teva Pharmaceuticals USA, Inc.$595
- plus $4K from 25 others
What the payments were for
- Consulting fees$1502%
- Speaking & faculty fees$2403%
- Food & beverage$8,62895%
- Education$871%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 23 | $1,373 |
| Novartis | 27 | $1,133 |
| EMD Serono, Inc. | 13 | $922 |
| AbbVie(2 entities) | 19 | $704 |
| UCB, Inc. | 15 | $626 |
| Teva Pharmaceuticals USA, Inc. | 8 | $595 |
| Sanofi | 4 | $594 |
| Acadia Pharmaceuticals Inc | 13 | $535 |
| Lilly USA, LLC | 8 | $509 |
| Amgen | 8 | $317 |
| SK Life Science, Inc. | 8 | $251 |
| E.r. Squibb & Sons, L.L.C. | 2 | $207 |
| AstraZeneca | 2 | $171 |
| Bristol Myers Squibb | 1 | $145 |
| Avanir Pharmaceuticals, Inc. | 2 | $136 |
| Argenx US, Inc. | 2 | $127 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $120 |
| Tanabe Pharma America, Inc. | 1 | $100 |
| Janssen Scientific Affairs, LLC | 1 | $66 |
| Pfizer | 3 | $53 |
| Livanova USA, Inc. | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Johnson & Johnson | 1 | $32 |
| PTC Therapeutics, Inc. | 1 | $32 |
| Sarepta Therapeutics, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Banner Life Sciences, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,104 in reported general payments places this provider in the 70th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 22 | $195,039 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 21 | $183,617 |
| MayzentSiponimod | 13 | $121,836 |
| Kesimpta PenOfatumumab | 14 | $121,599 |
| BetaseronInterferon Beta-1b | 12 | $115,976 |
| Aimovig AutoinjectorErenumab-Aooe | 86 | $82,913 |
| Glatiramer Acetate | 25 | $52,313 |
| Dimethyl Fumarate | 21 | $2,821 |
| Sumatriptan Succinate | 48 | $1,749 |
| Levetiracetam | 44 | $1,352 |
| Memantine Hcl | 11 | $1,089 |
| Phenytoin Sodium Extended | 26 | $909 |
| Gabapentin | 57 | $896 |
| Lacosamide | 15 | $712 |
| Cyclobenzaprine Hcl | 21 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $1,373 | $195,03922 claims |
| NovartisMayzent | $1,133 | $121,83613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 145 neurology providers in Nevada.
Other neurology in North Las Vegas
- Sherif HarawayNorth Las Vegas$10K
- Melissa BlochReno$883K
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Burton TabaacReno$287K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- G BigleyReno$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.